Patient-reported outcomes during repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis in the Phase 3 MycarinG and open-label extension studies

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

MG Symptoms PRO scores were developed by UCB¹ and have not been validated in any languages for use in MG. The MG Symptoms PRO analysis was part of the planned efficacy analysis; however, efficacy or clinical significance should be interpreted with caution.

1. Cleanthous S, et al. Orphanet J Rare Dis. 2021;16:457.